J Jesús López Tiro1, E Angélica Contreras Contreras2, M Elena Ramírez del Pozo2, J Gómez Vera2, D Larenas Linnemann3. 1. Department of Allergy and Clinical Immunology, H.R. Lic. Adolfo López Mateos, ISSSTE, Mexico City, Mexico. Electronic address: drlopeztiro@gmail.com. 2. Department of Allergy and Clinical Immunology, H.R. Lic. Adolfo López Mateos, ISSSTE, Mexico City, Mexico. 3. Allergy Staff, Hospital Medica Sur, Mexico City, Mexico.
Abstract
BACKGROUND: Even though there are multiple options for the treatment of asthma, there still exists a fair group of patients with difficult-to-control asthma. We describe for the first time the real-world effects of three-year omalizumab treatment on patients with difficult-to-control asthma, seen in a social security hospital in a Latin American country. METHODS: Difficult-to-control asthmatic patients from the out-patient clinic of a regional hospital were recruited to receive a three-year omalizumab course. Efficacy parameters were asthma control test (ACT) score; FEV1; daily beclomethasone maintenance dose; and unplanned visits for asthma exacerbations (emergency room (ER), hospitalisations, intensive care). RESULTS: 52 patients were recruited, 47 completed the three-year treatment (42 female, 15-67 years, mean age 43.5). Comparing efficacy parameters of the year before omalizumab with the 3rd year of omalizumab: mean ACT improved from 12.4 to 20.5, mean FEV1 from 66.3% (standard deviation (SD) 19.1%) to 88.4% (SD 16.2%) of predicted, while mean beclomethasone dose reduced from 1750 to 766 mcg/day and there was a significant reduction in patients experiencing ER visits (from 95% to 19%, p<0.0001), hospitalisation (38% to 2%, p<0.0001) and intensive care (4% to 0, NS). Five patients discontinued omalizumab, two because of an adverse event (anaphylaxis, severe headache, both resolved without sequelae). CONCLUSION: Omalizumab improved most clinical parameters of Mexican patients with difficult-to-control asthma. Especially the rates of ER visits and hospitalisation were significantly reduced, thus reducing costs. Omalizumab was generally well tolerated.
BACKGROUND: Even though there are multiple options for the treatment of asthma, there still exists a fair group of patients with difficult-to-control asthma. We describe for the first time the real-world effects of three-year omalizumab treatment on patients with difficult-to-control asthma, seen in a social security hospital in a Latin American country. METHODS: Difficult-to-control asthmatic patients from the out-patient clinic of a regional hospital were recruited to receive a three-year omalizumab course. Efficacy parameters were asthma control test (ACT) score; FEV1; daily beclomethasone maintenance dose; and unplanned visits for asthma exacerbations (emergency room (ER), hospitalisations, intensive care). RESULTS: 52 patients were recruited, 47 completed the three-year treatment (42 female, 15-67 years, mean age 43.5). Comparing efficacy parameters of the year before omalizumab with the 3rd year of omalizumab: mean ACT improved from 12.4 to 20.5, mean FEV1 from 66.3% (standard deviation (SD) 19.1%) to 88.4% (SD 16.2%) of predicted, while mean beclomethasone dose reduced from 1750 to 766 mcg/day and there was a significant reduction in patients experiencing ER visits (from 95% to 19%, p<0.0001), hospitalisation (38% to 2%, p<0.0001) and intensive care (4% to 0, NS). Five patients discontinued omalizumab, two because of an adverse event (anaphylaxis, severe headache, both resolved without sequelae). CONCLUSION:Omalizumab improved most clinical parameters of Mexican patients with difficult-to-control asthma. Especially the rates of ER visits and hospitalisation were significantly reduced, thus reducing costs. Omalizumab was generally well tolerated.
Authors: Jesús López-Tiro; Angelica Contreras-Contreras; M Eunice Rodríguez-Arellano; Paula Costa-Urrutia Journal: World Allergy Organ J Date: 2022-07-04 Impact factor: 5.516
Authors: Gregory M Lanza; John Jenkins; Anne H Schmieder; Aigul Moldobaeva; Grace Cui; Huiying Zhang; Xiaoxia Yang; Qiong Zhong; Jochen Keupp; Ismail Sergin; Krishna S Paranandi; Lindsey Eldridge; John S Allen; Todd Williams; Michael J Scott; Babak Razani; Elizabeth M Wagner Journal: Theranostics Date: 2017-01-01 Impact factor: 11.556
Authors: Luis Manuel Entrenas Costa; Francisco Casas-Maldonado; José Gregorio Soto Campos; Alicia Padilla-Galo; Alberto Levy; Francisco Javier Álvarez Gutiérrez; Ana P Gómez-Bastero Fernández; Concepción Morales-García; Rocío Gallego Domínguez; Gustavo Villegas Sánchez; Luis Mateos Caballero; Antonio Pereira-Vega; Cayo García Polo; Gerardo Pérez Chica; Juan José Martín Villasclaras Journal: Pharmacoecon Open Date: 2019-09